Pharmaxis’ (ASX: PXS) Bronchitol non‐antibiotic therapy has been accepted for used by the National Health Service in Scotland for the treatment of adult cystic fibrosis patients.
Bronchitol, a proprietary formulation of mannitol administered as a dry powder for inhalation, is accepted for use as an add‐on to best standard of care, in adults who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and who have a rapidly declining lung function and in whom other osmotic agents are considered unsuitable.
It is the first non‐antibiotic therapy to be accepted by the SMC for the treatment of cystic fibrosis and also means there is consistency throughout the UK in access to Bronchitol.
Phase 3 clinical trials have demonstrated that Bronchitol is an effective treatment with an acceptable safety profile.
Cystic fibrosis is one of the most common life‐threatening inherited diseases, with over 800 people affected in Scotland, including more than 450 adults. Patients can experience a rapid decline in lung function, with frequent respiratory infections that often require hospitalisation.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.